Rise for Rare - Black Women's Health Imperative

Travere Therapeutics Supports Rare Disease Diversity Coalition’s “Rise for Rare” Campaign

November 18, 2020 - Today, the Black Women’s Health Imperative (BWHI) announced the launch of a comprehensive multi-channel campaign entitled RISE for Rare (#riseforrare). 
Travere Circle Logo

Retrophin Announces Corporate Name Change to Travere Therapeutics, Inc.

SAN DIEGO, November 16, 2020 – Retrophin Inc., (NASDAQ: RTRX) today announced that the company has changed its global corporate name to Travere Therapeutics, Inc. Read the press release >
Lightbulb icon with Kidneys

Rare Kidney Disease Patients Deserve Better

Help us improve the lives of families living with these conditions by downloading our new community call to action at rarekidneyrevolution.com.
Travere Circle Logo

Travere Therapeutics: Our Brand Story

We come to work every day to do something extraordinary that can make a difference in the lives of the patients we serve. This is the core of who we are at Travere Therapeutics.
Travere Circle Logo

Retrophin Completes Acquisition of Orphan Technologies

SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). Read the press release >
Travere Circle Logo

Retrophin Reports Third Quarter 2020 Financial Results

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2020 financial results and provided a corporate update. Read the press release >
Travere Circle Logo

Retrophin Announces Agreement to Acquire Orphan Technologies

SAN DIEGO, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a definitive agreement to acquire Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58 for the treatment of classical homocystinuria (HCU). Read the press release >
Travere Circle Logo

Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined

SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined.  Read the press release >
Grace Whiting, National Alliance for Caregiving

Grace Whiting on Caregiving

,
On Rare Disease Day 2019, our team had the honor of speaking with Grace Whiting, president and chief executive officer of the National Alliance for Caregiving. Her compassion and professional energy to help caregivers is profound. We present the unedited words Grace shared with us here.
Travere Circle Logo

Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy (IgAN). Read the press release >